美国血液技术公司调整2027财年指引：摊薄后每股调整后收益与营收增长相若

美股速递05-07

美国血液技术公司(Haemonetics)在最新提交的SEC文件中，对2027财年业绩指引作出重要调整。根据披露信息，公司预计2027财年摊薄后每股调整后收益的增长水平将与营收增长保持基本同步。

这一调整反映出公司对未来财年盈利能力的预期与业务扩张速度相匹配。摊薄后每股收益作为衡量企业盈利能力的关键指标，其与营收增长的协同变化，通常被视为企业运营效率的重要参考依据。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1117554142?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-07 18:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117554142","market":"us","top_or_hot":-1,"title":"美国血液技术公司调整2027财年指引：摊薄后每股调整后收益与营收增长相若","media":"美股速递","content":"<p>美国血液技术公司(Haemonetics)在最新提交的SEC文件中，对2027财年业绩指引作出重要调整。根据披露信息，公司预计2027财年摊薄后每股调整后收益的增长水平将与营收增长保持基本同步。</p>\n<p>这一调整反映出公司对未来财年盈利能力的预期与业务扩张速度相匹配。摊薄后每股收益作为衡量企业盈利能力的关键指标，其与营收增长的协同变化，通常被视为企业运营效率的重要参考依据。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美国血液技术公司调整2027财年指引：摊薄后每股调整后收益与营收增长相若</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美国血液技术公司调整2027财年指引：摊薄后每股调整后收益与营收增长相若\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-07 18:16 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>美国血液技术公司(Haemonetics)在最新提交的SEC文件中，对2027财年业绩指引作出重要调整。根据披露信息，公司预计2027财年摊薄后每股调整后收益的增长水平将与营收增长保持基本同步。\n这一调整反映出公司对未来财年盈利能力的预期与业务扩张速度相匹配。摊薄后每股收益作为衡量企业盈利能力的关键指标，其与营收增长的协同变化，通常被视为企业运营效率的重要参考依据。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4198","symbol_name":"医疗保健用品","start_time":0,"source_url":"","article_id":"1117554142","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117554142","pubTimestamp":1778148978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"美国血液技术公司(Haemonetics)在最新提交的SEC文件中，对2027财年业绩指引作出重要调整。根据披露信息，公司预计2027财年摊薄后每股调整后收益的增长水平将与营收增长保持基本同步。\n这一调整反映出公司对未来财年盈利能力的预期与业务扩张速度相匹配。摊薄后每股收益作为衡量企业盈利能力的关键指标，其与营收增长的协同变化，通常被视为企业运营效率的重要参考依据。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4198":"医疗保健用品","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","IE00BLDYK493.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) INC","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU0205193047.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD)  ACC","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","HAE":"美国血液技术","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","LU0205194284.USD":"SCHRODER ISF US SMALL & MID-CAP EQUITY \"A\" (USD) INC AV","IE00B64QTZ34.USD":"NEUBERGER BERMAN US SMALL CAP \"A\" (USD) ACC","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D"},"translate_title":"U.S. Blood Technologies adjusts FY2027 guidance: Adjusted EPS on diluted basis matches top line growth","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HAE":1},"content_text":"美国血液技术公司(Haemonetics)在最新提交的SEC文件中，对2027财年业绩指引作出重要调整。根据披露信息，公司预计2027财年摊薄后每股调整后收益的增长水平将与营收增长保持基本同步。\n这一调整反映出公司对未来财年盈利能力的预期与业务扩张速度相匹配。摊薄后每股收益作为衡量企业盈利能力的关键指标，其与营收增长的协同变化，通常被视为企业运营效率的重要参考依据。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117554142","isCrawlerRequest":true}